• Cerulean (CERU) Phase 2 Results of CRLX101 for Renal Cell Carcinoma

       (0 reviews)

    Clinical and Regulatory
    Event Type: Phase 2 Results
    Timing: Q3 2016
    Designation(s): Fast Track, Orphan Drug

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Renal Cell Carcinoma
    Lead Indication?: Yes
    Treatment Name: CRLX101

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Cerulean
    Stock Symbol: CERU
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://ir.ceruleanrx.com/releasedetail.cfm?ReleaseID=968534
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement


    Mr. Guiffre  continued, "The rate of disease progression in patients appears to have slowed down recently in our blinded trial of CRLX101 in combination with Avastin® (bevacizumab) in relapsed renal cell carcinoma (RCC); accordingly, we now expect top-line results in the third quarter 2016."


      Report Event

    User Feedback

    There are no reviews to display.